For instance, hyper-activation of Lyn or Hck has been associated with imatinib resistance in CML patients and cell culture models [21]–[24], albeit the mechanisms by which these kinases contribute to imatinib resistance is not well understood. This evidence concerns the gene LYN and chronic myelogenous leukemia, BCR-ABL1 positive.